Welcome to our dedicated page for OPKO HEALTH SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OPKO HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OPKO HEALTH's regulatory disclosures and financial reporting.
OPKO Health filed its Q3 2025 10‑Q, reporting a profitable quarter driven by an asset sale. Total revenue was $151.7 million versus $173.6 million a year ago, with services at $95.2 million, products at $37.7 million, and transfer of intellectual property and other at $18.7 million. Operating income rose to $48.1 million from $14.2 million, aided by a $101.6 million gain on the sale of BioReference’s oncology diagnostics business to Labcorp.
Net income was $21.6 million (basic EPS $0.03), compared to $24.9 million last year. For the nine months, revenue was $458.4 million and net loss was $194.4 million, reflecting higher interest expense and the absence of prior‑year gains. Cash, cash equivalents and current restricted cash were $415.2 million, with total assets of $2.00 billion and total liabilities of $690.0 million.
The Labcorp oncology transaction delivered $192.5 million in consideration, including $173.3 million in cash and $19.2 million in escrow, plus up to $32.5 million in contingent consideration. OPKO continued its repurchase program, buying 24.3 million shares year‑to‑date for approximately $33.5 million, bringing total program spend to about $73.8 million. As of October 17, 2025, 767,701,280 common shares were outstanding. The company disclosed a foreign tax assessment of approximately $246 million; it has recorded a $9.9 million accrual related to uncertain tax positions.
OPKO Health (OPK) furnished an 8-K stating it issued a press release with operating and financial highlights for the quarter ended September 30, 2025. The release also explains how to access the company’s conference call covering third-quarter results and provides financial guidance. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and a copy of the press release is attached as Exhibit 99.1.
OPKO Health completed the sale of certain BioReference oncology and oncology-related laboratory testing business assets to Laboratory Corporation of America Holdings for up to $225,000,000 in cash. Of this amount, $192,500,000 was paid in cash at closing on September 15, 2025, with up to an additional $32,500,000 payable as contingent earnout consideration based on revenue from specified customer accounts. The company also issued a press release about the closing, furnished as Exhibit 99.1.
Phillip Frost M.D. and related entities reported multiple dispositions of OPKO HEALTH, INC. (OPK) common stock on 08/18/2025. The Form 4 shows a reported sale (transaction code G) of 440,000 shares for $0 and additional dispositions of 3,568,951 shares. Following the reported transactions, the filing lists 214,236,448 shares and 30,127,177 shares held indirectly by affiliated trusts and entities, with ownership described in footnotes clarifying trustee/beneficiary relationships. The filing is signed by Phillip Frost, M.D., individually and as trustee, indicating the report covers both his individual and related trust holdings.
OPKO HEALTH, INC. reported an insider-related open-market purchase of its common stock. On August 8, 2025, Frost Gamma Investments Trust, a trust entity associated with CEO and Chairman Phillip Frost, bought 675,000 shares at $1.32 per share in an indirect transaction.
Following this purchase, the filing shows 214,676,448 OPKO shares held indirectly in this trust. It also reports 3,568,951 shares held directly and 30,127,177 shares held indirectly through another related trust structure. The reporting person disclaims beneficial ownership of the trust-held securities except to the extent of any pecuniary interest.